These findings suggest that the lower CD32b expression in cells from females with CIS or MS may be a consequence of increased serum levels of BAFF or other B cell activating stimuli associated with MS, and raise the possibility that CD32b is downregulated via a negative feedback mechanism downstream of CD32b following B cell activation. This evidence concerns the gene FCGR2B and myeloid sarcoma.